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Abstract 
Pharmaceuticals and personal care products (PPCPs) are a contaminant class of worldwide 
concern. Their environmental omnipresence indicates they may be a potential source of global 
change, and ecosystem-scale impacts at non-lethal levels have not been fully explored. We used 
stream biofilms to assess ecosystem responses to PPCPs. Biofilms were cultivated in streams 
draining areas of different land use and then exposed to triclosan, diphenhydramine, and 
sulfamethoxazole-trimethoprim treatments. We found evidence that low levels of these PPCPs 
affected some, but not all, aspects of biofilm processes and bacterial community composition. 
Bacterial carbon uptake was reduced (p = 0.06) and we found shifts in biofilm community 
composition following treatments. However, maximum photosynthetic efficiency, 
decomposition, and microbial physiological profiles showed no significant effect of PPCPs. Still, 
changes in bacterial activity and composition suggest that PPCPs may act as ecological 
disruptors at low levels, and further research is needed to assess ecosystem-scale effects. 
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Introduction 
Freshwater ecosystems impact environmental, economic, and human health and provide 
important ecosystem services (Millennium Ecosystem Assessment 2005). With increasing 
urbanization, such systems are often contaminated with pollutants, the long-term ecological 
impacts of which are largely unknown (Malmqvist and Rundle 2002). Understanding how 
pollutants impact ecosystem processes is critical to conserving freshwater resources. Further, as 
the human population increases globally and landscapes shift to urban and agricultural uses, 
synthetic compound production and release into the environment has increased and has even 
outpaced known drivers of global change such as rising atmospheric CO2 and nutrient pollution 
(Bernhardt et al. 2017). As these synthetic compounds become more prevalent in waterways, it is 
important to understand their ecosystem-scale impacts. 
Pharmaceuticals and personal care products (PPCPs) are a class of pollutants of emerging 
concern (e.g., Daughton and Ternes 1999; Kolpin et al. 2002; Bernot et al. 2016; Bernhardt et al. 
2017). As these compounds intended for medicinal, industrial and personal use become more 
widespread, their presence in waterways becomes more prevalent. PPCPs enter freshwater 
systems through a variety of pathways, such as agricultural and livestock runoff, leaking sewer 
infrastructure in urban landscapes, and industrial and domestic waste (Ebele et al. 2017). Most 
wastewater treatment facilities are ill-equipped to remove these diverse organic compounds (Joss 
et al. 2006). As a result, a multitude of compounds have been detected in stream water across the 
United States and globally (Kolpin et al. 2002; Bernot et al. 2016; Bernhardt et al. 2017). The 
omnipresence of pharmaceutical contaminants in waterways at low, non-lethal concentrations 
demonstrates their potential to impact ecosystems through chronic exposure and bioaccumulation 
(Kolpin et al. 2002; Bernot et al. 2016). 
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The bioactive nature and chronic presence of PPCPs makes them potential ecological 
disruptors with the capacity to alter ecological processes (Daughton and Ternes 1999; Richmond 
et al. 2017). While the ecotoxicology of many of these compounds is understood, few studies 
have explored their ecological disrupting effects at environmentally relevant, non-lethal levels, 
and those that have largely focused on effects on animal behavior (Richmond et al. 2017). The 
impacts of PPCPs at non-lethal concentrations on ecosystem processes, such as photosynthesis 
and decomposition, is not well understood. 
In freshwater systems, particularly low-order streams, biofilms play an integral role in 
ecosystem processes (Figure 1). Composed mainly of algae, bacteria, and fungi, biofilms 
comprise a large source of primary production in stream ecosystems and form the foundation of 
the stream food web, providing food for stream macroinvertebrates and protozoa. These 
microorganism collectives are responsible for facilitating nutrient cycling, such as decomposition 
and nitrogen fixation. Biofilms likewise play an important role in dissolved organic carbon 
(DOC) dynamics and other biogeochemical processes in streams (e.g., Battin et al. 2003; Romani 
et al. 2004).  
 
Figure 1. The diverse roles of biofilms in stream ecosystems, adapted from “World’s water 
streams affected by pharmaceutical pollution” (Puiu 2013). 
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Recent studies focusing on biofilm response to pharmaceuticals have found measurable 
impacts, such as reduced microbial respiration and altered bacterial and algal communities 
(Wilson et al. 2003; Rosi-Marshall et al. 2013). For example, the antibiotics sulfamethoxazole-
trimethoprim and triclosan suppress algal growth (Teixeira and Granek 2017, Xin et al. 2017), 
and diphenhydramine, an antihistamine, suppresses algal growth and microbial respiration in 
biofilms (Rosi-Marshall et al. 2013). Bacterial richness and diversity are lower in rivers where 
pharmaceuticals are present, and triclosan reduces bacterial diversity, suggesting a shift in 
bacterial community composition (Drury et al. 2013; Drury et al. 2013). There is also evidence 
for the selection of antimicrobial-resistant microbes in the environment where pharmaceuticals 
are present (Magalhaes et al. 2016; Rosi et al. 2018). Previous research has documented the 
effects of PPCPs on aquatic systems, but few have investigated the effects at very low, 
environmentally relevant levels. 
Impacts of PPCPs on ecological processes may be influenced by interactions with other 
environmental stressors, such as nutrient and contaminant input as a result of different 
surrounding land uses. Land development can cause hydrologic alterations, nutrient enrichment 
and contaminant pollution, creating a number of stressors (Allan 2004). Agricultural land use 
may introduce excess nitrogen and phosphorus to streams through fertilizers, and streams with 
urban land use are subject to increased salinity and flashiness due to road salts and high amounts 
of impervious surfaces. Riparian clearing in land development can increase stream temperatures, 
and sedimentation can decrease the suitability of substrate for biofilm communities (Allan 2004). 
Further, previous research indicates that streams in less urban areas are more susceptible to 
pharmaceutical contaminants, possibly due to resistance from continuous exposure to 
contaminants in urban waterways (Rosi et al. 2018). The variable stressors of different land uses 
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shape microbial communities and therefore may influence their response to pharmaceutical 
exposure. 
The purpose of this study was to investigate the ecological effects of low doses of three 
common pharmaceuticals, triclosan, diphenhydramine, and sulfamethoxazole-trimethoprim, on 
stream biofilm structure and function in streams across a land use gradient. We hypothesized that 
due to the bioactive nature of pharmaceutical pollutants, biofilms exposed to such pollutants in 
low, environmentally relevant concentrations would show reduced bacterial activity, 
decomposition, photosynthetic potential, and reduced bacterial community diversity compared to 
controls. Additionally, because biofilm communities in agricultural and urban streams are more 
likely to be impacted from chronic exposure to other environmental stressors, we hypothesized 
that these communities would exhibit less of a response than communities from unimpacted, or 
natural, streams. To test these hypotheses, we collected biofilms on tiles in streams of variable 
land use and examined the bacterial community structure and function of biofilms following 
exposure to very low levels of pharmaceuticals in laboratory microcosm experiments. 
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Methods 
Experimental Set-Up 
To test the effects of PPCPs on ecological processes, we cultivated biofilms from streams 
of different land use on tiles and cotton strips to conduct manipulative experiments. We used 
microcosm experiments to assess the effects of three common pharmaceuticals on the ecological 
functioning of stream biofilms across varying land uses. Dissolved organic carbon (DOC) 
uptake, Pulse-Amplitude-Modulated (PAM) chlorophyll fluorescence, cotton strip 
decomposition experiments, and community-level physiological profiles were conducted to 
assess functional responses of biofilms to treatments. DNA analysis of the bacterial community 
was used to compare bacterial community composition of biofilms from different streams and 
after treatment with PPCPs. 
 
Study Sites 
 Biofilms were cultivated in six streams of the Huron River watershed that differed in land 
use. The streams were categorized as natural, agricultural, or urban based on the dominant land 
use. Intact natural area and impervious surface data made available in creekshed reports by the 
Huron River Watershed Council (HRWC) were used to categorize streams (Figure 2, Table 1). 
Millers Creek and Malletts Creek were classified as urban streams due to a high percentage of 
impervious surfaces (30% and 40%) and urban land use (80% and 85%). The streams 
categorized as agricultural and natural each had relatively high intact natural areas (30-42%) 
with low impervious surfaces (4-7%) and low urbanization (12-35%). The agricultural streams, 
Portage Creek and Mill Creek, had a higher percent of agricultural land use (33% and 47%). Hay 
Creek and Honey Creek were classified as natural streams with lower areas of agricultural use 
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(8% and 22%). Millers Creek and Malletts Creek have the smallest creekshed size (6.2 km2 and 
28.5 km2) and Portage Creek and Mill Creek have the largest creekshed size (204.6 km2 and 
370.4 km2). 
Twice during the summer of 2018, at each site, stream discharge, temperature, 
conductivity, and oxygen measurements were made, and water samples were collected for 
nutrient analysis in order to characterize the sites (Table 2). Millers Creek and Malletts Creek 
had the lowest stream discharge and notably higher conductivity (3.488 ms/cm and 2.487 ms/cm) 
than other sites. 
 
Figure 2. Map of study sites in the Huron River Watershed. 
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Table 1. Land use data for streams available through the Huron River Watershed Council and 
land use classification. 
 Creekshed Size Intact Natural Agriculture Urban 
Impervious 
Surfaces 
Land Use 
Classification 
Hay Creek 34.7 km2 30% 8% 35% 7% Natural 
Honey Creek 
(Livingston) 69.9 km
2 40% 22% 19% 4% Natural 
Portage Creek 204.6 km2 42% 33% 12% 5% Agricultural 
Mill Creek 370.4 km2 31% 47% 18% 4% Agricultural 
Millers Creek 6.2 km2 10% - 80% 30% Urban 
Malletts Creek 28.5 km2 8% 2% 85% 40% Urban 
 
 
Table 2. Stream characterization measurements during brick-tile placements and retrievals.* 
 Date Hay Creek Honey Creek 
Portage 
Creek Mill Creek 
Millers 
Creek 
Malletts 
Creek 
Stream 
Discharge 
(m3/s) 
26-Jun 0.0909 0.7812 0.6800 0.1082 0.0039 0.0079 
17-Jul 0.0244 0.3582 0.3563 0.0522 - - 
Temperature 
(°C) 
26-Jun 17.45 19.24 22.07 21.15 14.58 19.58 
17-Jul 20.17 22.34 21.67 18.68 16.86 21.1 
 
pH 
26-Jun 8.04 8.01 8.21 8.10 7.58 7.94 
17-Jul 8.16 7.97 8.06 8.14 7.68 7.95 
Conductivity 
(ms/cm) 
26-Jun 1.30 1.48 1.62 1.39 3.48 2.48 
17-Jul 1.80 2.38 3.23 2.45 3.54 4.75 
Oxygen 
(mg/L) 
26-Jun 8.84 9.39 8.27 8.70 7.69 8.51 
17-Jul 8.82 8.36 7.26 9.37 7.47 8.20 
Nitrogen 
(NO3) (µg/L) 
26-Jun 254.89 236.88 420.78 66.40 450.87 230.99 
17-Jul 308.38 277.30 186.84 127.39 256.85 190.69 
Phosphorus 
(PO4) (µg/L) 
26-Jun 3.65 3.40 3.67 3.60 4.01 6.67 
17-Jul 4.06 3.91 5.29 4.13 3.63 7.05 
*Dashes ( - ) indicate missing data. 
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Biofilm Cultivation 
Bricks were affixed with eighteen 2 cm x 2 cm unglazed ceramic tiles using inert rubber 
cement (VersaChem Mega Black O.E.M. High-Temp Silicone Gasket Maker). The brick-tile 
fixtures were autoclaved to ensure sterility and transported to streams inside autoclaved lidded 
plastic bins. The brick-tile fixtures were submerged at each stream site (four per site) and 
carefully pinned into place using landscape staples. Four bricks were placed in each of the six 
streams. Brick-tile fixtures remained in streams for 3 weeks to allow adequate biofilm growth. 
Following this period, they were retrieved and tiles were removed from bricks using sterilized 
pliers to prevent biofilm contamination between sites. 
Cotton strips prepared using the method described by Tiegs et al. (2013) were also 
submerged at each site, secured using zip ties and polypropylene twine, and held in place with 
steel rebar. Cotton strips remained in streams for a period of 1 week in order to establish 
adequate biofilm inoculation and to prevent too much decomposition of the cotton strips before 
experimental laboratory use. The strips were retrieved and transported in separate ziplock bags to 
prevent cross contamination. 
 
Pharmaceutical Treatments 
The pharmaceutical treatments for this experiment included 5 µg/L triclosan (an 
antibacterial agent), 5 µg/L diphenhydramine (an antihistamine), and 2.5:2.5 µg/L 
sulfamethoxazole-trimethoprim (antibiotics frequently prescribed together) (Table 3). All 
pharmaceuticals were chosen based on their common presence in streams and their 
concentrations to reflect commonly observed levels, as few studies have explored the ecological 
disrupting effects at environmentally relevant, nonlethal concentrations (Kolpin et al. 2002; 
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Larsson et al. 2007; Bernot et al. 2016; Bradley et al. 2017; Richmond et al. 2017). Triclosan is a 
broad-spectrum antibacterial and antifungal that inhibits the growth of bacteria by blocking lipid 
synthesis (McMurry et al. 1998). Diphenhydramine is a common antihistamine that blocks the 
H1 histamine receptor and may inhibit some bacteria and alter bacterial communities (Wolfson 
et al. 2018). Sulfamethoxazole is a sulfonamide and trimethoprim inhibits folic acid synthesis. 
Together with trimethoprim, this combination inhibits two steps in the enzymatic pathways 
required for DNA synthesis in bacteria (Tenover 2006). 
Pharmaceuticals were prepared as 10 mg/L solutions, then diluted to µg/L doses (Table 
3). Diphenhydramine, sulfamethoxazole and trimethoprim were dissolved in water, and we used 
5 mL of ethanol per 1 L stock solution to facilitate dissolving triclosan into solution to a final 
negligible ethanol experimental concentration of 0.00025%. 
 
 
Table 3. Characteristics of pharmaceutical treatments. 
Name Chemical Formula CAS Use Experimental Concentration 
Triclosan C12H7Cl3O2 3380-34-5 Antimicrobial 5µg/L 
Diphenhydramine C17H21NO 58-73-1 Antihistamine 5µg/L 
Sulfamethoxazole- 
trimethoprim 
C10H11N3O3S, 
C14H18N4O3 
723-46-6 
738-70-5 
Antibiotic 
combination 2.5:2.5µg/L 
 
Effects of Pharmaceuticals on DOC Uptake 
DOC uptake assays were conducted by measuring the difference in DOC uptake between 
treatments and controls as a proxy for bacterial activity. Inoculated tiles were placed in 
individual conical tubes; dosed with triclosan, diphenhydramine, or sulfamethoxazole-
trimethoprim treatment; and compared to controls. By measuring the change in DOC 
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concentration over the three-week incubation period, we compared differences in biofilm DOC 
uptake among controls (no pharmaceuticals added) and pharmaceutical treatments. 
Individual 50 mL sterile plastic conical tubes filled with 40 mL of sterile filtered stream 
water (Grade GF/F glass microfiber filter, followed by 0.22 µm membrane filtered to remove 
bacteria) and a tile containing cultivated biofilm were spiked with DOC (n = 5; Table 4). This 
DOC spike established a starting concentration for the biofilm community to consume. To 
prepare the DOC spike, 10 g of black maple leaves were added to 1 L megapure water and kept 
on a shaker table at 90 rpm for 24 hours. The leachate was filtered with a Grade GF/F glass 
microfiber filter, followed with a 0.22 µm filter to sterilize. Four milliliters of filtered leachate 
was added to tubes of 40 mL stream water for a ratio of 1:10. 
 
Table 4. Stream DOC concentrations for each site and experimental concentrations with DOC 
leachate spike. 
 26-Jun Conc. (ppm) 17-Jul Conc. (ppm) Experimental DOC Concentration with leachate (ppm) 
Hay Creek 
(natural) 9.28 4.24 83.69 
Honey Creek 
(natural) 7.33 4.01 90.59 
Portage Creek 
(agricultural) 15.05 12.60 82.29 
Mill Creek 
(agricultural) 10.57 6.01 84.05 
Millers Creek 
(urban) 4.46 2.84 91.92 
Malletts Creek 
(urban) 7.51 11.90 87.88 
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Triclosan (5 µg/L), diphenhydramine (5 µg/L), and sulfamethoxazole-trimethoprim 
(2.5:2.5 µg/L) treatments were added and tubes were loosely capped to prevent evaporation and 
debris from contaminating tubes. Tubes were kept continuously on a shaker plate in the dark to 
ensure solutions were properly mixed, to allow sufficient airflow, and to prevent carbon 
production of photosynthetic microbes. Following a three-week incubation period, water samples 
were taken from each tube, filtered (Grade GF/F glass microfiber filter) and acidified with 20 mL 
trace metal grade hydrochloric acid. DOC concentrations were measured via wet combustion as 
non-purgeable organic carbon on a Shimadzu TOC-5000 model total organic carbon analyzer, 
taking measurements in triplicates. DOC concentrations were determined by comparing values to 
known potassium hydrogen phthalate standards. DOC uptake was calculated as  𝐷𝑂𝐶$%&'() = 	𝐷𝑂𝐶,-,&,'. −	𝐷𝑂𝐶0,-'. 
where tubes containing 0.22 µm filtered stream water and filtered leachate established the 
starting DOC concentration. The control for this experiment included biofilms absent of 
treatment to determine DOC uptake under normal conditions. We also included controls of 
stream water absent of biofilm or treatment, and DI water absent of biofilm or treatment to 
determine if some compound present in the tile or stream water was responsible for changes in 
DOC. Experimental biofilm tiles from Portage Creek and Malletts Creek were saved for DNA 
analysis. 
 
Effects of Pharmaceuticals on Maximum Photosynthetic Efficiency 
To assess changes in algal community physiology in response to low levels of 
pharmaceuticals, we measured the photosynthetic potential of biofilms in treatments compared to 
controls. We determined photosynthetic potential using chlorophyll fluorescence, which uses 
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light re-emitted by chlorophyll molecules to measure the maximum efficiency of PSII 
photochemistry (Consalvey et al. 2005). Individual tiles were placed in petri dishes and 15 mL 
Grade GF/F glass microfiber filtered stream water was added until the surface of the tile was 
submerged (n = 5). Triclosan (5 µg/L), diphenhydramine (5 µg/L), and sulfamethoxazole-
trimethoprim (2.5:2.5 µg/L) treatments were added with 5 replicates. The petri dishes were 
incubated at 25 °C under 11.25 µmol/s·m2 controlled light conditions. Chlorophyll fluorescence 
measurements were taken 2 days and 6 days following treatment (or control). None of the tiles 
showed any change in photosynthetic potential on Day 2, so we gave them an additional 
designated pharmaceutical dose of increasing strength (5, 10, 20, 40 and 80 µg/L) (Table 5). We 
then took measurements 6 days after the initial dose (4 days after additional dose). 
 
Table 5. Additional dose of designated pharmaceutical treatments for chlorophyll fluorescence.* 
Replicate Initial Dose (µg/L) 
Final Dose 
(µg/L) 
1 5 5 
2 5 10 
3 5 20 
4 5 40 
5 5 80 
*Sulfamethoxazole-trimethoprim doses were 2.5:2.5 µg/L per 5 µg/L dose. 
 
Effects of Pharmaceuticals on Decomposition 
To measure the effects of pharmaceutical exposure on decomposition rates, we used the 
cotton strip assay (Tiegs et al. 2013). We focused on a single pharmaceutical, triclosan, due to its 
antimicrobial properties, common occurrence in waterways, and presence in a large number of 
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common household products, such as antimicrobial hand soaps, cleaning products, and a wide 
variety of other consumer products (Bedoux et al. 2011). Cotton strips prepared using the method 
described by Tiegs et al. (2013) were submerged at each site, secured using zip ties and 
polypropylene twine, and held in place with steel rebar. After 1 week, cotton strips were 
collected from the field and placed in 50 mL conical tubes with 0.22 µm filtered stream water 
and 5 µg/L triclosan treatment (or control without triclosan; n = 5). Cotton strips were suspended 
in solution and capped loosely. Tubes were incubated at in the dark at 25 °C for 3 weeks, then 
removed, cleaned with an ethanol wash, and dried thoroughly at 40 ºC. Tensile strength was 
tested using a tension meter (Chatillon LTCM-5 motorized test stand and Chatillon DFI-100 
digital force gauge) in order to determine the impact of pharmaceutical treatments on 
decomposition rates. Percent tensile strength loss per day for each stream was then calculated as 
%	𝑆𝑡𝑟𝑒𝑛𝑔𝑡ℎ	𝑙𝑜𝑠𝑠	𝑝𝑒𝑟	𝑑𝑎𝑦 = 1 − 𝑆𝑡𝑟𝑒𝑛𝑔𝑡ℎ	𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡/𝑐𝑜𝑛𝑡𝑟𝑜𝑙	𝑠𝑡𝑟𝑖𝑝𝑠𝑆𝑡𝑟𝑒𝑛𝑔𝑡ℎ	𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒	𝑠𝑡𝑟𝑖𝑝𝑠 ×100 ÷ 𝑇𝑖𝑚𝑒 
By assessing the rate of tensile strength loss, we were able to determine the decomposition rate 
of the cotton strip. 
 
Effects of Pharmaceuticals on Community-Level Physiological Profiles 
We used BIOLOG Microbial Community Analysis EcoPlates (Catalog No. 1506; 
https://www.biolog.com/products-portfolio-overview/microbial-community-analysis-with-
ecoplates/) to determine changes in biofilm community functioning following exposure to 
pharmaceuticals. EcoPlates contain 31 different common carbon sources and the pattern of use of 
these substrates can provide a physiological profile of the community via color development of 
the wells for each substrate. 
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Biofilm slurries were incubated with pharmaceutical treatments and added to EcoPlates. 
Biofilm slurries were made by carefully scraping five tiles from each site using sterile technique 
into a combined slurry and thoroughly mixing using a vortex to ensure identical starting bacterial 
communities. Three milliliters biofilm slurry and 10 mL filtered stream water were added to 15 
mL conical tubes. Triclosan (5 µg/L), diphenhydramine (5 µg/L), and sulfamethoxazole-
trimethoprim (2.5:2.5 µg/L) treatments were added to the slurry and incubated in the dark at 20 
°C for 1 week. After 1 week, biofilm slurries were aliquoted into the EcoPlates (n = 1). Control 
groups without pharmaceuticals added had two replicates and pharmaceutical treatments groups 
had no replication. Plates were incubated at 20 °C and measurements taken at 5 days. Average 
Metabolic Response (AMR) was determined by calculating the mean value for plate color 
development and Shannon-Wiener diversity (H’) was calculated using  𝐻K = 	−Σ𝑝, 𝑙𝑛𝑝,  
to quantify biofilm response, where 𝑝, is the proportion of total well development for each 
substrate. A multivariate principal components analysis (PCA) on the covariance matrix was 
used to determine patterns in substrate usage across treatments and land-use variables. 
 
Effects of Pharmaceuticals on Bacterial Community Composition 
To determine the effects of land use and pharmaceutical exposure on bacterial 
community composition, 16S rRNA genes were sequenced using a general bacterial primer 
(515F forward and 806R reverse), which targets the V4 region of the 16S small subunit rRNA. 
We analyzed biofilms samples from all six streams to assess patterns related to land use and 
samples from pharmaceutical treatments and controls of Portage Creek and Malletts Creek in the 
DOC uptake assay to assess patterns related to treatments. Tiles were carefully scraped with a 
 15 
razor blade into a slurry using sterile technique. The slurry for each stream and treatment (or 
control) contained the pooled biofilms of five tiles (n = 1). DNA was isolated using QIAGEN 
PowerSoil DNA Isolation Kit, and samples were sent to MR DNA sequencing services for 
analysis (http://www.mrdnalab.com, Shallowater, TX, USA). The samples were amplified using 
single-step 30 cycle PCR with QIAGEN HotStarTaq Plus Master Mix Kit, sequenced using the 
Ion S5 XL torrent platform and data were processed using a proprietary analysis pipeline (MR 
DNA, Shallowater, TX, USA) and QIIME analysis, providing bacterial identification counts and 
relative abundance data. We assessed the overall bacterial community by calculating richness (S) 
as the total number of genera (not species) present and Shannon-Wiener diversity (H’) as  𝐻K = 	−Σ𝑝, 𝑙𝑛𝑝,  
where 𝑝, is the proportion of total counts for each genus to quantify biofilm response. We looked 
for trends in the bacterial community composition between treatments and controls as well as 
across land use, focusing on notable community composition changes in class and genus. 
 
Statistical Analyses 
 We used a mixed-model analysis of variance (ANOVA) to test the effects of 
pharmaceuticals and land use on responding variables (DOC uptake, chlorophyll fluorescence, 
and decomposition responses) (Myers and Well 2002). If there were no significant interactions 
between pharmaceutical and land-use, we performed post-hoc tests to determine the effects. In 
particular, a Bonferroni-based post-hoc t-test was used to determine the effects of land use on 
DOC uptake. Statistical analyses were performed using Systat 10.2 Software with a statistical 
significance level of ⍺  = 0.05 and a Bonferroni-based t-test significance level of ⍺  = 0.017. Data 
that did not meet normality or equality of variance assumptions were transformed using 
 16 
exponential transformations (x4 for photosynthetic potential and x3 for decomposition) in order to 
meet assumptions. 
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Results 
Effects of Pharmaceuticals on DOC Uptake 
 Control biofilms consumed DOC by an average of 65.45 ppm, or 2.88 mg (0.14 mg/day) 
for a 2 cm x 2 cm area. Our results showed that land use had a significant effect on DOC uptake 
(p = 0.02), with biofilms from agricultural streams consuming the most DOC and biofilms from 
natural streams consuming the least. Pharmaceutical treatments reduced DOC uptake (p = 0.06). 
In all streams except Mill Creek, DOC uptake was reduced by triclosan treatments by as much as 
6.9% (Millers Creek) and diphenhydramine treatments by as much as 7.7% (Honey Creek) 
compared to controls. In all sites except Mill Creek and Millers Creek, DOC uptake was reduced 
in sulfamethoxazole-trimethoprim treatments by as much as 3.5% (Portage Creek) compared to 
controls (Figure 3). There was no interaction between land use and pharmaceutical treatment (p 
= 0.32), indicating that land use did not influence biofilm response to pharmaceutical treatments. 
Data for additional controls is available in Appendix A. 
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Figure 3. DOC uptake in biofilms exposed to triclosan, diphenhydramine, sulfamethoxazole-
trimethoprim, and control conditions across natural, agricultural, and urban land uses. Error bars 
indicate standard error. Letters indicate significant differences. n = 5, except for triclosan at 
Honey Creek (n = 4). 
 
Effects of Pharmaceuticals on Maximum Photosynthetic Efficiency 
We found no significant effect of pharmaceuticals or land use on maximum 
photosynthetic efficiency after two days of exposure (p = 0.28 and p = 0.68, respectively). Other 
than a notable low fluorescence in the Hay Creek control group, no streams showed a difference 
between treatments and controls (Figure 4). Following the extra pharmaceutical dose to observe 
the effect of different concentrations, no clear pattern in fluorescence with pharmaceutical 
concentration emerged across pharmaceutical or land use (Figure 5; for example, R2 = 0.00061, 
R2 = 0.16339, and R2 = 0.0269 for triclosan, diphenhydramine and sulfamethoxazole-
trimethoprim treatments respectively in Honey Creek). The data for each site and treatment is 
available in Appendix A. 
0
10
20
30
40
50
60
70
Hay Honey Portage Mill Millers Malletts
C
ha
ng
e 
in
 D
O
C
 C
on
ce
nt
ra
tio
n 
(p
pm
)
Natural      Agriculture   Urban
Control Triclosan Diphen. Sulf.-trim.
A B C
 19 
 
Figure 4. Maximum photosynthetic efficiency of photosystem II (YII) in biofilms 2 days 
following exposure to triclosan, diphenhydramine, sulfamethoxazole-trimethoprim, and control 
conditions across natural, agriculture, and urban land uses. Error bars indicate standard error.      
n = 5. 
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(a) Triclosan 
 
(b) Diphenhydramine 
 
(c) Sulfamethoxazole-trimethoprim 
 
Figure 5. Regression of maximum photosynthetic efficiency of photosystem II (YII) of (a) 
triclosan, (b) diphenhydramine, and (c) sulfamethoxazole-trimethoprim treatments in Honey 
Creek biofilms 4 days post-treatment spike (6 days post initial treatment). 
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Effects of Pharmaceuticals on Decomposition 
Exposure to pharmaceuticals had no significant effect on decomposition of cotton strips 
(p = 0.34). While triclosan exposure decreased decomposition activity by 59% in Mill Creek 
(agricultural) and 19% in Millers Creek (urban), there was no difference in loss of tensile 
strength (decomposition) between controls and triclosan treatments incubated in the other 
streams (Figure 6). Further, no clear pattern emerged among land use (p = 0.33). 
 
Figure 6. Percent loss of tensile strength per day in controls and triclosan treatments across 
natural, agricultural, and urban land uses. Lines represent standard error. n = 5. 
 
Effects of Pharmaceuticals on Community-Level Physiological Profiles 
A principal components analysis of substrate utilization showed no clear groupings 
across pharmaceutical treatment or land use (Figure 7). At Day 5 measurements, the percent 
variance explained by the first two axes was 43%. Average metabolic response (AMR) and 
Shannon-Wiener diversity (H’) also showed no clear pattern across pharmaceutical or land use 
(Table 6). AMR in Honey Creek biofilms was 17% and 18% lower in triclosan and 
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diphenhydramine treatments compared to controls (Table 6). In contrast, the sulfamethoxazole-
trimethoprim treatment was 47% higher than the control, but there was little difference in AMR 
at other sites. 
 
Table 6. Day 5 average metabolic response (AMR) and Shannon-Wiener diversity (H’) in 
biofilms across pharmaceutical treatments and land use. 
 
 
AMR 
Natural Agricultural Urban 
Hay Honey Portage Mill Millers Malletts 
Control 
1.04 1.79 1.07 1.22 1.59 1.25 
1.11 1.70 1.30 1.54 1.56 1.19 
Triclosan 1.24 1.44 1.18 1.33 1.62 1.25 
Diphen. 1.05 1.43 1.07 1.21 1.69 1.32 
Sulf.-trim. 1.30 1.45 1.23 1.31 1.55 1.49 
    
 
 
H’ 
Natural Agricultural Urban 
Hay Honey Portage Mill Millers Malletts 
Control 
3.00 3.36 3.12 3.08 3.32 3.13 
3.08 3.35 3.22 3.22 3.27 3.13 
Triclosan 3.13 3.23 3.28 3.07 3.28 3.15 
Diphen. 2.95 3.26 3.14 3.17 3.28 3.17 
Sulf.-trim. 3.08 3.18 3.24 3.05 3.29 3.18 
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5 days 
   
Figure 7. Multivariate principal components analysis (PCA) on the covariance matrix of 
EcoPlate substrate utilization of biofilm slurry exposed to triclosan, diphenhydramine, 
sulfamethoxazole-trimethoprim, and controls after 5 days. 
 
Effects of Pharmaceuticals on Bacterial Community Composition 
Across the six streams, there was no consistent pattern in community composition with 
land use. Genera in Hay Creek (natural) and Malletts Creek (urban) had the lowest value of 
richness (S), and Portage Creek (agricultural) had the highest (Table 7). While Malletts Creek 
had the lowest value, Shannon-Wiener diversity (H’) in genera did not differ substantially across 
land use (Table 7). 
Pharmaceutical treatments showed little overall change in S compared to controls, with 
the exception of a much lower S in the triclosan treatment of Portage Creek (Table 8). 
Surprisingly, we found a slightly lower H’ in control biofilms than in pharmaceutical-treated 
biofilms in both Portage Creek and Malletts Creek. 
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Table 7. Richness (S) and Shannon-Wiener diversity (H’) in bacterial genera across land use 
collected from each site. 
Natural S H’ 
Hay Creek 742 5.28 
Honey Creek 786 5.27 
Agricultural   
Portage Creek 822 5.27 
Mill Creek 774 5.32 
Urban   
Millers Creek 779 5.36 
Malletts Creek 723 4.89 
 
 
Table 8. Richness (S) and Shannon-Wiener diversity (H’) in bacterial genera across 
pharmaceutical treatments from the DOC uptake assay. 
Portage Creek 
(agricultural) S H’ 
Control 648 4.53 
Triclosan 602 4.64 
Diphenhydramine 680 4.81 
Sulf.-trimethoprim 675 4.88 
Malletts Creek 
(urban)   
Control 671 4.57 
Triclosan 673 4.96 
Diphenhydramine 664 5.02 
Sulf.-trimethoprim 644 5.02 
 
  
There were some differences in community composition at the taxonomic resolution of 
class across sites, but differences in bacterial abundance were site-specific rather than consistent 
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with land use categories. Malletts Creek (urban) had over 1,000% more Oscillatoriophycideae 
relative to other sites, 72-81% less Actinobacteria, and 60-80% less Deltaproteobacteria. Millers 
Creek (urban) had 40-49% less Alphaproteobacteria. 
Notable changes in bacterial community composition were observed between control and 
pharmaceutical treatments, most notably in triclosan and diphenhydramine treatments. The class 
Gammaproteobacteria was 31%, 32%, and 27% lower in Portage Creek biofilms and 66%, 69%, 
and 52% lower in Malletts Creek biofilms after exposure to triclosan, diphenhydramine and 
sulfamethoxazole-trimethoprim treatments, respectively (Figures 8a and 8b). Several genera 
within this class were consistently lower in treatment groups compared to controls, while other 
genera were higher with pharmaceutical exposure (Figures 8c and 8d). In particular, Alcanivorax 
was 95%, 85%, and 67% lower in Portage Creek biofilms and > 99%, > 99%, and 74% lower in 
Malletts Creek biofilms after exposure to triclosan, diphenhydramine and sulfamethoxazole-
trimethoprim treatments, respectively (Table 9). Similarly, Halioglobus was 95%, 71%, and 37% 
lower in Portage Creek biofilms and > 99%, > 99%, and 74% lower in Malletts Creek biofilms 
after exposure to triclosan, diphenhydramine and sulfamethoxazole-trimethoprim treatments, 
respectively. 
The genus Pseudomonas was notably higher in treatments than controls, 169%, 146%, 
and 92% higher in triclosan, diphenhydramine and sulfamethoxazole-trimethoprim treatments in 
Portage Creek biofilms (Table 9). Malletts Creek also had a higher percentage of Pseudomonas 
in triclosan and diphenhydramine-treated biofilms (70% and 21%), but Pseudomonas was 39% 
lower than controls in the sulfamethoxazole-trimethoprim treatment. The full list of class and 
genus data are available in Appendix B. 
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(a) Portage Creek, class 
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(b) Malletts Creek, class 
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(c) Portage Creek, genus (excluding genera < 1% for all groups)) 
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(d) Malletts Creek, genus (excluding genera < 1% for all groups) 
 
 
Figure 8. Bacterial community composition in (a) Portage Creek (class), (b) Malletts Creek 
(class), (c) Portage Creek (genus), and (d) Malletts Creek (genus) biofilms following exposure to 
pharmaceutical treatments. 
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Table 9. Total genus percentages (%) for Alcanivorax, Halioglobus, and Pseudomonas following 
exposure to pharmaceutical treatments. 
 Control Triclosan Diphenhydramine Sulf.-trimethoprim 
Portage Creek 
(agricultural) 
    
Alcanivorax 14.9 0.7 2.3 4.9 
Halioglobus 7.7 0.4 1.0 2.0 
Pseudomonas 4.4 11.8 10.8 8.4 
Malletts Creek 
(urban) 
    
Alcanivorax 16.5 0.1 0.1 4.2 
Halioglobas 7.4 0.0 0.0 1.9 
Pseudomonas 3.9 6.6 4.7 2.4 
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Discussion 
We assessed the effects of pharmaceutical compounds on biofilm communities across a 
land use gradient using five different response variables and found some evidence of reduced 
function and change in bacterial community composition in biofilms exposed to pharmaceuticals, 
although we found no evidence to suggest that land use influences the response. Decomposition, 
photosynthetic potential, and community-level physiological profiles were not affected by 
pharmaceutical treatment or land use, but we found a significant response in DOC uptake to land 
use (p = 0.02) and a decrease in DOC uptake with pharmaceutical treatment that was nearly 
significant (p = 0.06). In addition, metagenomic sequencing results showed several distinct shifts 
in bacterial community composition in response to low doses (5 µg/L) of pharmaceuticals. These 
results suggest that PPCPs may impact some, but not all, aspects of stream biofilm structure and 
function. 
 
Effects of Pharmaceutical Treatments on Biofilm Functioning 
Our findings suggest that the bacterial activity of stream biofilms has the potential to be 
affected by PPCP exposure. The effect of pharmaceuticals on bacterial activity via DOC uptake 
was nearly significant (p = 0.06), indicating that biofilms may be sensitive to these compounds. 
These results suggest that many streams may be negatively affected by low-level pharmaceutical 
exposure. The effect size, while small (a maximum effect size of 7.25%), extrapolated over 
larger areas could impact stream carbon budgets. Our control biofilms on 2 cm x 2 cm tiles 
consumed an average of 0.137 mg carbon (C) per day. Extrapolated to a 1 km reach of a 10 m 
wide stream, a 5% reduction in DOC consumption would decrease DOC uptake by 5.14 kg C 
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over a 30-day period, or by 30.8 kg C for a 6-month growing season, increasing organic carbon 
export downstream. 
Our results are consistent with other findings that biofilm microbial respiration is 
suppressed in response to pharmaceutical exposure, both alone or in combination with other 
pharmaceuticals, although other studies have found much larger responses. For example, the 
antidepressants fluoxetine and citalopram reduced biofilm respiration by more than 43%, and 
caffeine, diphenhydramine, the antacid cimetidine, and the antibiotic ciprofloxacin suppressed 
respiration by 49-97% (Rosi-Marshall et al. 2013; Richmond et al. 2016). Our results from 5 
µg/L concentrations suggest that bacterial activity may be impacted at even very low 
concentrations, although the higher concentrations used in other studies (≥ 40µg/L) elicited a 
stronger effect. 
 We found no effect of pharmaceuticals on photosynthetic potential, as measured by the 
maximum photosynthetic efficiency of PSII, even at higher pharmaceutical concentrations (80 
µg/L). Previous research indicates that some, but not all, pharmaceutical compounds suppress the 
processes of algal assemblages. While low amounts of triclosan do not appear to impact final 
algal biomass, diphenhydramine reduces gross primary production and sulfamethoxazole-
trimethoprim reduces algal growth (Wilson et al. 2003; Rosi-Marshall et al. 2013; Teixeira and 
Granek 2017). We did not see similar effects in photosynthetic potential, and one possibility for 
our results may be the mechanism by which the pharmaceuticals in question affect 
photosynthetic microorganisms. Our method assessed photosynthetic potential using PAM 
chlorophyll fluorescence by using light re-emitted by chlorophyll molecules to measure PSII 
photochemistry efficiency (Consalvey et al. 2005). This suggests that the impacts pharmaceutical 
contaminants have on photosynthetic microorganisms do not target specific photosynthetic 
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machinery. Rather than impacting the mechanisms of photosynthesis directly, pharmaceuticals 
may indirectly affect photosynthesis by suppressing algal growth. This toxicity would 
nonetheless disrupt the flow of energy, potentially altering food web dynamics. Other 
investigators have reported mixed results of the effects of PPCPs on algae, with only certain 
pharmaceuticals or mixtures of pharmaceuticals impacting algal processes (Wilson et al. 2003; 
Rosi-Marshall et al. 2013), or only some parameters of algal processes being affected and not 
others (Richmond et al. 2016). This suggests that algae may only be susceptible to certain 
pharmaceuticals or that some parameters may be more sensitive indicators of algal functioning 
than others. 
While there was no significant effect of triclosan or land use on decomposition, one 
urban (Millers Creek) and one agricultural (Mill Creek) stream showed a strong negative 
response to triclosan. Decomposition in triclosan treatments was reduced by 19% in Millers 
Creek and 59% in Mill Creek. Triclosan is a broad-spectrum antimicrobial which affects both 
bacteria and fungi, so these results suggest that some factor specific to those streams may be 
affecting how biofilms respond to triclosan. While we did not assess fungal community 
composition, a difference in fungi decomposers in these sites may account for these differences, 
particularly if fungi are more sensitive to triclosan than bacteria. 
Community-level physiological profiles showed little effect of pharmaceutical treatments 
and land use. AMR and Shannon-Wiener diversity (H’) did not differ between treatments and 
controls. However, DNA results showed noticeable shifts in treatments compared to control 
groups, such as Alcanivorax and Halioglobus in the class Gammaproteobacteria lower in 
pharmaceutical treatments, and Pseudomonas (also of the class Gammaproteobacteria) higher in 
treatments. This shift in community composition without a similar shift in physiological profiles 
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indicates that while the bacterial community may be altered, similarly-functioning groups may 
compensate for the loss of any single group. However, another possibility for the lack of 
response in microbial function may be the short duration of pharmaceutical exposure. The 
community-level physiological profile experiment consisted of a short-term exposure of 7 days, 
while we found greater changes in the long-term bacterial activity experiment, which ran for 21 
days. Similarly, previous research has found that longer-term (21+ days) exposures to stressors 
impact biofilm communities more than short-term exposures (Teixeira and Granek 2017; 
Romero et al. 2019). This may be explained by the extracellular polymeric substance (EPS), 
which provides structural support and a protective barrier for biofilm communities. The 
polysaccharides and proteins that make up this barrier confers tolerance against antimicrobial 
agents (Flemming and Wingender 2010). Therefore, the protective elements in EPS could 
prevent contaminants at low concentrations from penetrating the community within for a short 
period. 
 
Effects of Pharmaceuticals on Bacterial Community Composition 
The lack of a consistent pattern between genera richness (S) and Shannon-Wiener 
diversity (H’) in pharmaceutical treatments indicates that while overall diversity of bacterial 
genera may not be impacted, the relative abundances of distinct groups may be influenced by 
pharmaceuticals. We found little difference in S between pharmaceutical treatments and controls 
in Malletts Creek biofilms and lower S in triclosan-treated Portage Creek biofilms. H’ was lower 
in control and sulfamethoxazole-trimethoprim-treated biofilms than in triclosan and 
diphenhydramine-treated biofilms in Malletts Creek, and was only slightly lower in control and 
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triclosan-treated biofilms in Portage Creek. The discrepancy between S and H’ results suggests 
that relative abundance is being impacted. 
Several bacterial groups showed profound differences in abundance between controls and 
treatments. The class Gammaproteobacteria was lower by 27% to 32% in Portage Creek and 
52% to 69% in Malletts Creek. Within the Gammaproteobacteria class, we found that the notable 
shifts in the abundance of distinct genera. Alcanivorax and Halioglobus showed notably lower 
abundance in treatments compared to controls. Alcanivorax was lower by 67% to 95% in Portage 
Creek and 74% to > 99% in Malletts Creek biofilms in response to pharmaceutical treatments, 
and Halioglobus was lower by 37% to 95% in Portage Creek and 74% to > 99% in Malletts 
Creek biofilms. The genus Pseudomonas, also within the Gammaproteobacteria class, was more 
abundant in treatments, with the most substantial changes by an increase of 169% and 146% in 
response to triclosan and diphenhydramine treatments in Portage Creek biofilms. Our results are 
consistent with previous findings, showing that Pseudomonas and its parent class, 
Gammaproteobacteria, were abundant following pharmaceutical treatments (Collado et al. 2013; 
Rosi-Marshall et al. 2013). The Pseudomonas genus is a common environmental bacteria 
frequently associated with biofilms (Cole 1982). This genus is known for its metabolic diversity 
and ability to persist in environmental conditions that other bacteria cannot tolerate, and 
antibiotic resistance has been observed in the pathogenic Pseudomonas aeruginosa in streams 
receiving wastewater effluent (Magalhaes et al. 2016). Our results are consistent with the idea 
that Pseudomonas thrives in an environment other bacterial genera may not be able to tolerate, 
and that pharmaceutical contaminants act as a pressure for the selection of antimicrobial-resistant 
bacteria. Pharmaceutical contaminants, even in very low concentrations, can therefore effectively 
alter bacterial community composition. 
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Effects of Land Use 
DOC uptake differed across land use (p = 0.02) but did not predict biofilm response to 
pharmaceuticals. The DOC uptake assay was conducted under controlled laboratory conditions 
during incubation, so this result is not site-specific but may be attributed to differences in the 
biofilms across land use. We did not measure biomass, but a greater biomass on tiles from 
agricultural streams may account for their higher rates of DOC consumption. Another possibility 
may be differences in bacterial community composition across different land uses. While we 
found no direct interactive effects of land use on bacterial activity, previous research indicates 
that microbial communities in urban waterways show pharmaceutical resistance due to 
continuous contaminant exposure (Rosi et al. 2018). However, the complex effects of 
pharmaceuticals and land use may influence bacterial activity in ways difficult to predict. 
Aquatic systems are often subject to multiple pollutants, particularly in urban watersheds, and 
the effects of multiple stressors are complex and difficult to anticipate (Romero et al. 2019). 
Furthermore, while individual PPCP contaminants are typically found in low concentrations, 
they are often detected in large combinations with other PPCPs (Kolpin et al. 2003; Bartelt-Hunt 
et al. 2009; Bernot et al. 2016). Each contaminant has unique chemical properties which 
influence its ease of removal, persistence in the environment, biological pathways it impacts, and 
interactive effects in combination with other contaminants. Combinations of individual 
compounds to form “chemical cocktails” may have unexpected interactive effects not anticipated 
in analysis of their individual effects (Kaushal et al. 2018). Our knowledge is limited on the ways 
in which multiple stressors interact with synthetic compounds to impact ecological processes, 
and future research should focus on how combinations of such stressors interact with PPCPs to 
provide a more comprehensive approach to studying impacts on ecological processes. 
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Conclusions 
 We found that low levels of PPCPs have the potential to impact DOC uptake and 
bacterial community composition, although we did not detect effects on maximum 
photosynthetic efficiency, decomposition or physiological profiles. One important ecosystem 
function, DOC consumption, decreased (nearly significant; p = 0.06) following exposure to trace 
amounts of single pharmaceutical contaminants and significantly differed across land-use types. 
Responses at extremely low treatment levels suggests that these compounds have the capacity to 
impact ecosystem processes, particularly as PPCPs are often detected in combinations in the 
environment. However, further research is required to determine the specific mechanisms by 
which they impact biofilms and the extent to which these processes may be affected. The three 
tested pharmaceuticals did not impact PSII in photosynthesis, but they may impact 
photosynthetic microorganisms through some other mechanism, such as affecting algal biomass 
or chlorophyll a. Bacterial community composition may be influenced by the presence of 
pharmaceuticals, as we observed decreases in Alcanivorax and Halioglobus genera and an 
increase in the Pseudomonas genera following treatments indicate a shift to more drug-tolerant 
groups. Community composition changes in response to PPCPs may impact bacterial function, 
but additional information is required to understand whether a change in diversity would impact 
ecological processes. The long-term impacts of PPCPs on biofilm communities may be stronger 
than short-term effects, and the complex relationships of multiple stressors combined with 
PPCPs on stream ecosystems is not well understood and should be further explored. 
PPCPs and their metabolites pose a risk for aquatic ecosystems in a multitude of ways, 
from aquatic organisms to energy and nutrient transformation. Few studies have explored the 
ecological disrupting effects of these contaminants at environmentally relevant, non-lethal levels. 
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Other variables such as time scale and interactions with other environmental stressors should be 
investigated. Exploring the ecological costs of pharmaceutical contaminants in aquatic 
ecosystems will better inform regulations and remediations for the health of aquatic systems. 
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Appendix A: Biofilm Functioning Experimental Data 
Table 10. DOC uptake assay data of DOC consumption concentrations (ppm).* 
 Natural Agricultural Urban 
Hay Honey Portage Mill Millers Malletts 
Control 59.38 64.30 64.16 66.54 64.83 68.60 
63.05 65.82 68.78 59.63 66.96 66.48 
64.47 66.56 68.72 64.93 66.31 63.76 
64.50 65.54 69.03 64.95 66.64 68.23 
60.79 63.27 65.10 70.68 66.99 63.71 
Triclosan 62.26 61.51 64.41 66.23 61.98 62.05 
60.86 61.94 66.07 67.52 60.53 64.99 
60.93 61.01 64.25 66.50 60.76 64.12 
61.70 62.38 62.95 70.43 62.41 61.33 
62.23 - 62.92 62.08 63.03 63.35 
Diphenhydr
amine 
59.30 60.88 63.53 67.63 62.74 61.77 
59.60 62.58 66.21 69.64 60.55 63.61 
61.74 60.81 65.36 66.92 60.60 64.01 
61.99 56.70 65.38 66.20 62.09 62.49 
61.84 59.58 64.35 71.09 69.04 63.46 
Sulfamethox
azole-
trimethopri
m 
61.47 62.86 64.77 66.97 68.27 62.48 
61.41 64.55 65.05 65.69 67.52 65.31 
60.79 63.70 64.44 63.11 61.71 65.52 
60.35 62.08 66.43 62.16 68.87 63.87 
59.89 64.80 63.52 67.95 64.92 62.84 
*A dash ( - ) indicates missing data. 
 
Table 11. Stream DOC concentrations with DOC spike, additional controls. 
 
Filtered stream water + DOC 
spike 
(ppm) 
Control - 
Filtered stream water, 
no biofilm, 
no treatment 
(ppm) 
Control - 
DI water, 
no biofilm, 
no treatment 
(ppm) 
(Hay) 82.29 (Hay) 74.97 1.61 
(Honey) 84.05 (Honey) 75.30 1.44 
(Portage) 91.92 (Portage) 85.85 1.18 
(Mill)  87.88 (Mill) 78.9051 1.26 
(Millers) 83.69 (Millers) 70.95 1.76 
(Malletts) 90.59 (Malletts) 84.16 - 
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Table 12. PAM chlorophyll fluorescence data (YII). 
 Natural Agricultural Urban 
Hay Honey Portage Mill Millers Malletts 
Control 
 
 
0.64 0.62 0.61 0.64 0.62 0.63 
0.37 0.65 0.60 0.66 0.64 0.62 
0.46 0.65 0.60 0.63 0.64 0.63 
0.45 0.62 0.59 0.63 0.67 0.63 
0.68 0.61 0.59 0.66 0.64 0.63 
Triclosan 0.57 0.63 0.61 0.67 0.62 0.64 
0.61 0.64 0.64 0.65 0.61 0.63 
0.67 0.64 0.63 0.64 0.63 0.63 
0.65 0.65 0.61 0.65 0.67 0.63 
0.66 0.64 0.61 0.66 0.60 0.62 
Diphenhydra
mine 
0.61 0.60 0.62 0.65 0.64 0.63 
0.65 0.61 0.63 0.64 0.62 0.63 
0.62 0.63 0.61 0.65 0.62 0.65 
0.58 0.65 0.59 0.63 0.62 0.63 
0.63 0.64 0.61 0.63 0.64 0.64 
Sulfamethox
azole-
trimethopri
m 
0.66 0.63 0.62 0.64 0.62 0.63 
0.71 0.60 0.64 0.64 0.64 0.62 
0.33 0.62 0.62 0.63 0.63 0.62 
0.64 0.65 0.65 0.65 0.62 0.63 
0.63 0.64 0.62 0.64 0.62 0.63 
 
Table 13. Cotton strip assay data (percent loss tensile strength per day). 
 Natural Agricultural Urban 
Hay Honey Portage Mill Millers Malletts 
Control 
  
  
2.31 2.17 2.32 1.68 2.33 2.56 
1.81 2.44 2.20 0.79 2.52 2.72 
1.72 1.92 2.18 1.04 2.51 2.47 
2.13 1.41 2.29 0.45 2.67 2.70 
2.02 1.47 2.63 2.13 2.78 2.62 
Triclosan 
  
  
1.96 2.13 2.21 0.22 2.02 2.85 
2.14 1.61 2.56 0.87 2.15 2.61 
1.46 2.09 2.42 0.21 2.01 2.44 
2.11 1.68 2.39 0.86 1.89 2.73 
1.97 1.88 2.37 0.32 2.23 2.56 
 
  
 47 
Table 14. Community-level physiological profile BIOLOG plate Shannon-Wiener diversity (H’) 
data. 
 Natural Agricultural Urban Hay Honey Portage Mill Millers Malletts 
Day 0 
Control 2.13 1.68 0.25 2.63 0.00 2.68 0.49 2.53 1.89 0.00 2.70 2.93 
triclosan 3.05 2.71 0.82 2.79 0.00 2.07 
Diphen. 0.00 2.29 2.60 0.60 2.73 2.62 
Sulf.-trim. 1.55 1.68 2.85 2.78 2.68 0.00 
Day 3 
Control 2.89 3.25 3.02 2.99 3.22 2.99 2.91 3.26 3.07 3.09 3.18 2.96 
Triclosan 0.00 3.14 3.13 2.99 3.26 3.04 
Diphen. 2.87 3.09 3.03 3.06 3.22 3.05 
Sulf.-trim. 2.98 3.02 3.02 2.99 3.17 3.06 
Day 5 
Control 3.00 3.36 3.12 3.08 3.32 3.13 3.08 3.35 3.22 3.22 3.27 3.13 
Triclosan 3.13 3.23 3.28 3.07 3.28 3.15 
Diphen. 2.95 3.26 3.14 3.17 3.28 3.17 
Sulf.-trim. 3.08 3.18 3.24 3.05 3.29 3.18 
 
Table 15. Community-level physiological profile BIOLOG plate average metabolic response 
(AMR) data. 
 Natural Agricultural Urban Hay Honey Portage Mill Millers Malletts 
Day 0 
Control 0.01 -0.01 -0.01 0.02 -0.06 0.04 -0.06 0.03 0.01 -0.04 0.02 0.04 
Triclosan 0.03 0.03 -0.06 0.03 -0.08 0.02 
Diphen. -0.04 0.03 0.03 -0.04 0.01 0.03 
Sulf.-trim. 0.00 0.01 0.04 0.02 0.04 -0.06 
Day 3 
Control 0.83 1.35 0.91 1.01 1.25 0.87 0.68 1.30 0.92 1.17 1.24 0.92 
Triclosan 0.96 1.10 1.03 1.17 1.31 0.96 
Diphen. 0.75 1.14 0.91 0.95 1.32 0.96 
Sulf.-trim. 1.00 1.10 0.89 0.98 1.12 1.06 
Day 5 
Control 1.04 1.79 1.07 1.22 1.59 1.25 1.11 1.70 1.30 1.54 1.56 1.19 
Triclosan 1.24 1.44 1.18 1.33 1.62 1.25 
Diphen. 1.05 1.43 1.07 1.21 1.69 1.32 
Sulf.-trim. 1.30 1.45 1.23 1.31 1.55 1.49 
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Appendix B: Bacterial Community Experimental Data 
Table 16. Relative abundance of bacterial classes (%) from tiles at the end of the DOC uptake 
assays in controls and pharmaceutical treatments in Portage Creek. Samples were pooled from 5 
tiles (n = 1). 
Class Control Triclosan Diphenhydramine Sulf.-trimethoprim 
Acidobacteriia 1.93 1.76 3.83 3.19 
Flavobacteriia 1.08 2.81 1.47 1.98 
Bacilli 0.76 2.18 0.35 0.39 
Sphingobacteriia 4.08 5.45 8.92 8.52 
Betaproteobacteria 6.86 6.10 6.82 6.21 
Bacteroidia 0.26 0.27 0.41 1.26 
Verrucomicrobiae 1.44 1.48 1.80 2.61 
Alphaproteobacteria 23.06 30.85 25.85 23.43 
Gammaproteobacteria 35.77 24.62 24.17 26.19 
Cyanobacteria 0.28 0.08 0.23 0.27 
Clostridia 2.14 1.64 1.42 1.79 
Oscillatoriophycideae 0.11 0.13 0.24 0.15 
Actinobacteria 8.34 7.12 6.29 6.76 
Gemmatimonadetes 0.52 1.32 0.94 0.79 
Planctomycetia 2.90 2.83 3.21 2.62 
Cytophagia 1.63 1.96 2.32 2.13 
Deltaproteobacteria 4.16 5.29 6.37 6.13 
Other (<1% for all 
groups) 4.68 4.08 5.33 5.58 
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Table 17. Relative abundance of bacterial classes (%) from tiles at the end of the DOC uptake 
assays in controls and pharmaceutical treatments in Malletts Creek. Samples were pooled from 5 
tiles (n = 1). 
Class Control Triclosan Diphenhydramine Sulf.-trimethoprim 
Acidobacteriia 1.71 2.68 2.82 2.24 
Flavobacteriia 2.93 3.21 3.40 3.44 
Bacilli 0.19 0.19 0.23 0.27 
Sphingobacteriia 5.79 10.39 10.10 5.70 
Betaproteobacteria 7.44 6.67 6.76 5.32 
Bacteroidia 0.20 0.29 0.32 0.16 
Verrucomicrobiae 1.54 2.53 3.20 2.00 
Alphaproteobacteria 23.77 35.34 32.44 30.66 
Gammaproteobacteria 34.97 11.85 10.69 16.73 
Cyanobacteria 0.93 0.15 0.20 1.73 
Clostridia 0.93 1.35 1.27 1.11 
Oscillatoriophycideae 2.85 1.24 1.37 7.99 
Actinobacteria 2.30 5.28 4.84 5.00 
Gemmatimonadetes 0.73 1.51 1.47 1.20 
Planctomycetia 2.32 3.28 3.66 3.29 
Cytophagia 1.88 1.62 2.48 1.75 
Deltaproteobacteria 4.90 7.53 8.35 6.39 
Other (<1% for all 
groups) 4.61 4.89 6.40 5.02 
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Table 18. Relative abundance of bacterial classes (%) from tiles from each stream. Samples were 
pooled from 5 tiles (n = 1). 
Class Natural Agricultural Urban Hay Honey Portage Mill Millers Malletts 
Nitrospira 1.25 1.71 0.89 1.01 0.51 0.20 
Acidobacteriia 3.95 3.59 3.02 3.51 1.75 1.39 
Flavobacteriia 3.88 5.44 3.07 2.84 4.42 4.24 
Bacilli 1.03 1.45 0.62 0.86 0.58 0.23 
Sphingobacteriia 7.19 5.11 8.06 9.20 7.57 13.71 
Betaproteobacteria 9.64 7.64 10.36 9.96 10.31 7.52 
Bacteroidia 1.42 1.13 1.54 2.55 3.08 0.41 
Verrucomicrobiae 4.00 2.63 2.97 3.16 2.31 3.28 
Alphaproteobacteria 18.33 19.00 19.67 18.31 10.96 21.70 
Gammaproteobacteria 8.07 8.75 10.55 7.72 13.16 8.93 
Cyanobacteria 2.15 5.21 5.34 0.48 0.35 5.93 
Clostridia 1.89 2.11 2.57 2.93 2.73 2.23 
Oscillatoriophycideae 0.88 0.98 0.59 0.45 0.29 11.30 
Actinobacteria 11.14 9.42 7.60 10.34 10.09 2.14 
Gemmatimonadetes 0.99 0.84 0.68 0.62 0.78 0.97 
Planctomycetia 3.11 3.51 4.57 4.21 2.50 3.50 
Anaerolineae 3.01 2.29 2.18 2.55 1.96 0.27 
Cytophagia 3.98 3.91 3.88 5.37 6.52 6.06 
Deltaproteobacteria 8.53 8.63 6.86 7.68 13.84 2.73 
Other (<1% for all 
groups) 5.55 6.63 4.96 6.27 6.31 3.25 
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Table 19. Relative abundance of bacterial genera (%) from tiles at the end of the DOC uptake 
assays in controls and pharmaceutical treatments in Portage Creek. Samples were pooled from 5 
tiles (n = 1). 
Genus Control Triclosan Diphenhydramine Sulf.-trimethoprim 
Devosia 0.53 2.62 1.31 1.37 
Desulfomicrobium 0.00 0.00 0.03 0.04 
Rhodoplanes 1.10 0.74 0.99 0.81 
Caulobacter 0.72 2.21 1.53 1.62 
Hyphomicrobium 2.29 2.00 2.24 0.95 
Hydrogenophaga 1.36 0.19 0.67 0.78 
Lewinella 1.08 1.47 2.92 2.31 
Cytophaga 0.79 1.02 1.20 1.23 
Aquimonas 0.07 0.07 0.15 0.04 
Terrimonas 0.91 1.44 2.53 2.39 
Cyanobacterium 0.11 0.12 0.23 0.16 
Nitratireductor 0.10 0.07 0.32 0.15 
Steroidobacter 1.23 1.31 1.93 1.99 
Hyphomonas 0.22 0.58 0.45 0.31 
Acinetobacter 0.55 5.48 2.42 3.09 
Pseudomonas 4.39 11.83 10.82 8.44 
Rhodobacter 5.52 6.02 4.23 5.17 
Rhizobium 0.72 1.30 1.21 0.49 
Polyangium 0.48 1.05 0.64 1.05 
Cystobacter 0.02 0.39 0.10 0.19 
Arthrobacter 2.32 2.26 2.20 2.05 
Prosthecobacter 0.29 0.41 0.49 0.54 
Acidobacterium 1.77 1.68 3.53 2.99 
Woodsholea 0.25 0.54 0.35 0.45 
Halioglobus 7.69 0.40 1.00 1.98 
Rhizomicrobium 0.08 1.16 0.10 0.07 
Alcanivorax 14.92 0.69 2.25 4.86 
Methylosinus 1.14 1.18 1.03 0.84 
Pirellula 0.90 0.99 0.88 0.80 
Hirschia 0.04 0.10 0.13 0.03 
Mesorhizobium 0.69 0.34 1.55 0.73 
Anaeromyxobacter 0.49 1.07 0.85 0.69 
Agrobacterium 0.81 1.08 0.52 0.39 
Verrucomicrobium 0.71 0.79 0.80 0.94 
Roseomonas 0.92 0.82 0.63 1.01 
Haliscomenobacter 0.49 0.72 1.31 1.26 
Thiothrix 1.08 0.01 0.40 0.01 
 52 
Flavobacterium 0.66 2.14 0.74 1.21 
Clostridium 1.57 1.07 0.64 0.95 
Gemmatimonas 0.52 1.32 0.94 0.79 
Novosphingobium 0.41 0.96 0.87 1.04 
Exiguobacterium 0.50 1.21 0.09 0.07 
Other (<1% for all 
groups) 39.56 39.17 42.78 43.73 
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Table 20. Relative abundance of bacterial genera (%) from tiles at the end of the DOC uptake 
assays in controls and pharmaceutical treatments in Malletts Creek. Samples were pooled from 5 
tiles (n = 1). 
Genus Control Triclosan Diphenhydramine Sulf.-trimethoprim 
Devosia 1.36 2.49 2.09 1.77 
Desulfomicrobium 0.04 0.10 2.07 0.02 
Rhodoplanes 0.46 0.54 0.94 0.96 
Caulobacter 0.54 2.26 1.49 1.39 
Hyphomicrobium 1.53 2.08 1.70 2.69 
Hydrogenophaga 0.41 0.38 0.42 0.40 
Lewinella 1.82 2.95 3.36 1.56 
Cytophaga 0.83 0.84 1.17 0.83 
Aquimonas 1.04 0.10 0.12 0.43 
Terrimonas 1.33 3.51 2.50 1.86 
Cyanobacterium 2.62 1.15 1.28 7.42 
Nitratireductor 1.31 1.20 1.82 1.35 
Steroidobacter 0.89 1.07 1.19 1.15 
Hyphomonas 1.44 2.18 2.12 1.23 
Acinetobacter 0.17 0.56 0.22 0.38 
Pseudomonas 3.88 6.61 4.68 2.38 
Rhodobacter 0.88 1.57 1.40 2.03 
Rhizobium 2.66 3.08 2.94 1.76 
Polyangium 0.34 1.04 0.75 0.58 
Cystobacter 1.03 0.78 0.42 1.15 
Arthrobacter 0.05 0.11 0.08 0.09 
Prosthecobacter 0.37 1.04 1.03 0.58 
Acidobacterium 1.57 2.33 2.42 2.00 
Woodsholea 1.36 1.47 1.65 0.94 
Halioglobus 7.40 0.02 0.03 1.91 
Rhizomicrobium 0.85 1.45 1.46 0.70 
Alcanivorax 16.45 0.07 0.06 4.25 
Methylosinus 0.43 0.90 0.93 0.93 
Pirellula 0.73 1.26 1.27 1.10 
Hirschia 0.78 1.49 1.04 0.61 
Mesorhizobium 0.74 1.76 1.61 1.03 
Anaeromyxobacter 0.49 1.14 0.70 0.76 
Agrobacterium 0.10 0.17 0.11 0.13 
Verrucomicrobium 0.49 0.83 1.16 0.56 
Roseomonas 0.33 0.59 0.48 0.68 
Haliscomenobacter 0.50 1.29 0.97 0.53 
Thiothrix 0.52 0.01 0.01 0.97 
 54 
Flavobacterium 2.20 2.10 1.99 2.57 
Clostridium 0.49 0.53 0.69 0.57 
Gemmatimonas 0.73 1.51 1.47 1.20 
Novosphingobium 1.04 1.83 1.31 1.31 
Exiguobacterium 0.02 0.01 0.02 0.01 
Other (<1% for all 
groups) 37.79 43.56 46.83 45.20 
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Table 21. Relative abundance of bacterial genera (%) from tiles from each stream. Samples were 
pooled from 5 tiles (n = 1). 
Genus Natural Agricultural Urban Hay Honey Portage Mill Millers Malletts 
Syntrophus 0.95 1.12 0.62 0.56 0.31 0.07 
Rhodoplanes 1.41 1.18 0.99 1.71 0.63 0.17 
Desulfobacterium 0.12 0.13 0.15 0.06 1.56 0.04 
Dechloromonas 0.03 0.09 0.22 0.06 1.68 0.24 
Luteolibacter 1.50 0.45 0.53 0.65 0.26 1.61 
Mariniflexile 0.00 1.16 0.00 0.00 0.09 0.05 
Myxosarcina 0.00 0.48 1.37 0.00 0.00 0.16 
Burkholderia 1.02 1.24 1.73 1.50 0.64 0.53 
Sphingobacterium 0.51 0.57 1.01 0.58 0.64 0.56 
Hyphomicrobium 1.87 2.98 2.70 1.85 0.83 1.69 
Arenimonas 0.27 0.17 0.32 0.51 0.44 1.52 
Lewinella 1.70 1.13 2.44 2.64 1.40 2.80 
Cytophaga 1.48 1.87 2.07 1.88 3.98 2.57 
Haliea 0.36 0.70 1.87 0.72 2.15 0.87 
Chamaesiphon 1.46 1.53 2.27 0.24 0.00 1.15 
Terrimonas 0.79 0.44 1.21 1.65 0.98 2.85 
Cyanobacterium 0.82 0.92 0.59 0.42 0.26 10.39 
Chroococcidiopsis 0.00 0.01 0.04 0.00 0.06 1.32 
Steroidobacter 1.09 1.36 1.91 1.65 1.22 0.75 
Pseudomonas 0.32 0.42 0.42 0.34 1.65 0.31 
Rhodobacter 2.24 2.55 2.99 2.28 0.93 3.65 
Lacibacter 0.14 0.09 0.09 0.31 0.11 1.75 
Rhizobium 0.84 0.79 0.60 0.62 0.63 1.06 
Leadbetterella 1.17 0.50 0.40 1.86 0.19 1.00 
Bacteroides 0.65 0.47 0.70 1.00 0.94 0.21 
Acidobacterium 3.62 3.45 2.88 3.17 1.69 1.24 
Pelobacter 1.77 1.81 0.92 1.28 1.33 0.35 
Chelatococcus 1.03 1.50 0.29 0.70 0.02 0.48 
Nitrospira 1.13 1.57 0.83 0.94 0.47 0.19 
Methylobacter 0.62 0.48 1.05 0.44 0.19 0.09 
Pseudanabaena 0.34 1.59 0.73 0.03 0.00 0.31 
Pleurocapsa 0.09 1.24 0.26 0.00 0.00 0.16 
Methylosinus 0.51 0.65 1.23 0.63 0.16 0.48 
Pirellula 0.98 1.22 1.58 1.49 1.08 1.41 
Geobacter 1.75 1.52 1.50 1.42 4.12 0.33 
Anaeromyxobacter 1.02 0.96 0.63 1.14 0.92 0.13 
Pedosphaera 0.58 0.54 0.51 0.51 1.06 0.37 
 56 
Solitalea 0.18 0.20 0.23 0.15 1.33 0.27 
Tetrasphaera 0.13 0.11 0.04 0.20 1.05 0.14 
Verrucomicrobium 1.43 1.17 1.15 1.32 0.63 0.70 
Gaiella 1.27 0.85 0.72 1.39 0.27 0.09 
Haliscomenobacter 1.61 1.46 1.12 1.91 1.09 2.76 
Levilinea 1.39 0.78 0.77 1.19 0.77 0.08 
Flavobacterium 2.92 3.38 1.94 2.02 2.91 3.21 
Clostridium 0.75 0.81 1.55 1.40 1.55 1.52 
Conexibacter 1.71 1.44 0.79 1.52 1.11 0.32 
Novosphingobium 1.11 0.73 0.54 0.60 0.29 1.54 
Sediminibacterium 0.92 0.24 0.53 0.30 0.15 1.55 
Other (<1% for all 
groups) 52.38 49.95 50.99 53.15 56.22 44.98 
 
